(Q37407844)

20 August 2017

1 reference

title

Monitoring strontium ranelate therapy in patients with osteoporosis (English)

1 reference

20 August 2017

0 references

1 reference

D L Kendler

1

1 reference

20 August 2017

J D Adachi

series ordinal

2

1 reference

20 August 2017

R G Josse

series ordinal

3

1 reference

20 August 2017

D O Slosman

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

6 March 2009

1 reference

Osteoporosis International

20 August 2017

published in

1 reference

20 August 2017

volume

20

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

1101-1106

1 reference

Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses

20 August 2017

cites work

1 reference

12 December 2020

Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry

1 reference

12 December 2020

Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

A review of strontium ranelate and its effect on DXA scans

1 reference

12 December 2020

Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone.

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

Incorporation and distribution of strontium in bone

1 reference

12 December 2020

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

12 December 2020

Long-term effect of strontium ranelate treatment on BMD.

1 reference

12 December 2020

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

1 reference

12 December 2020

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

1 reference

12 December 2020

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

1 reference

12 December 2020

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Fracture risk remains reduced one year after discontinuation of risedronate

1 reference

12 December 2020

Bone densitometry: an update

1 reference

12 December 2020

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

1 reference

12 December 2020

Strontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action

1 reference

12 December 2020

Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats

1 reference

12 December 2020

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

1 reference

12 December 2020

Noninvasive measurement of bone strontium

1 reference

12 December 2020

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

1 reference

12 December 2020

Predictive Value of BMD for Hip and Other Fractures

1 reference

12 December 2020

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate

1 reference

12 December 2020

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

1 reference

12 December 2020

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S00198-009-0886-1

Identifiers

DOI

1 reference

20 August 2017

1 reference